Targeted medicine emerged with the development of modern molecular biology and cellular biology; it is medicine that developed based on the differences between the tumor cells and normal cells in molecular biological characteristics.
Targeted medicine is typically used alone or in combination with chemotherapeutic drugs; clinically well-validated medicine can be used as first-line, second-line or third-line therapy. Currently, targeted medicine used within the country are mainly introduced from European and American companies and are of high prices. However, the use of targeted medicine may vary according to the patient’s specific conditions, and clinically, whether the patient’s genes change may have important implications on the efficacy of the targeted medicine. Effective medication plans can be provided in clinic through monitoring the use of targeted medicine.
Product list
Items | Medication | Types | Method |
EGFR gene mutation | Gefitinib | NSCLC | ARMS+PNA |
K-ras gene 7 mutation | Cetuximab | NSCLC Colorectal cancer | ARMS+PNA |
B-raf gene V600 mutation | Zelboraf | Colorectal cancer Thyroid cancer Lung cancer | ARMS+PNA |
N-ras gene mutation | Cetuximab | Colorectal cancer | ARMS |
ROS1 fusion gene | Crizotibib | NSCLC | One-step RT-PCR |
ALK+ROS1fusion gene | Crizotibib | NSCLC | One-step RT-PCR |
RET fusion gene | Crizotibib | NSCLC | One-step RT-PCR |
RET gene mutation | Differentiation of hereditary and sporadic patients | MENⅡ | ARMS |
c-kit gene mutation（7 locus） | Imatinib | GIST | ARMS |
c-kit gene mutation（1 locus） | Imatinib | GIST | ARMS |
PDGFRA gene D842V mutation | Imatinib | GIST | ARMS |
BCR-ABL gene T315I mutation | Imatinib | CML | ARMS |
BCR-ABL fusion gene | Gleevec | CML | One-step RT-PCR |
JAK2 gene V617F mutation | MPN identification&diagnosis | MPD | ARMS |
ALK fusion gene | Crizotibib | NSCLC | One-step RT-PCR |
PIK3CA gene mutation | Gefitinib | NSCLC | ARMS |